Amnion-derived stem cells: in quest of clinical applications.
Level 5 - mechanism / opinion, no new human data
Narrative review and theoretical model with no new human trial data or systematic synthesis
PubMed 21596003 · doi:10.1186/scrt66
What was done
The authors reviewed published literature on human perinatal stem cells isolated from term placentae, focusing on amniotic epithelial (AE) cells. They described a model theory explaining why term amniotic epithelium contains a high proportion of stem-cell marker-positive cells, reviewed preclinical therapeutic applications, and analyzed potential biological and methodological pitfalls in amnion-derived stem cell research.
What was found
The abstract reports no quantitative data or statistical comparisons. It qualitatively notes that term human amniotic epithelial cells display stem-cell markers, possess pluripotent differentiation capacity, and present fewer ethical issues and less DNA damage than alternative stem cell sources.
Why it matters
Amnion-derived stem cells represent an accessible, non-controversial biological source derived from discarded tissue that may bypass key ethical and genomic-damage concerns in regenerative medicine.
Limits
This is a narrative review presenting theoretical models and summarizing previous findings without a systematic search methodology, meta-analysis, or primary clinical data. Clinical safety, long-term differentiation fidelity, and in vivo efficacy in humans are not established in the abstract.
Cited by
- context The human placenta is a rich source of pluripotent stem cells that can differentiate into heart, liver, or brain cells.